Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2014 Oct 15;13(12):2784–2792. doi: 10.1158/1535-7163.MCT-14-0593

Figure 3. High dose SAHA treatment lowers the efficacy of brentuximab vedotin.

Figure 3

Cells were treated with (A) 1 µM SAHA for 48 hours or (B) 2.5 µM SAHA for 24 hours or DMSO control prior to treatment for 72 hours with 1 nM brentuximab vedotin. Viability was assessed by MTS assay. Each data point was normalized to its own untreated control to account for viability differences unrelated to brentuximab vedotin treatment. *p<0.05, **p<0.005, ***p<0.0005 as determined by t-test.